Clinical trial / 2015
White button mushroom powder showed biological activity in biochemically recurrent prostate cancer.
Thirty-six patients with rising prostate-specific antigen levels received escalating doses of white button mushroom powder in a phase I trial. No dose-limiting toxicities occurred, and the overall prostate-specific antigen response rate was 11%. Complete responses occurred in two patients receiving 8 and 14 g/d, with reductions to undetectable levels lasting 49 and 30 months.
- Study type
- Phase I trial
- Who was studied
- 36 patients with biochemically recurrent prostate cancer
- What was measured
- Tolerability, toxicity, serum prostate-specific antigen levels
THE PAPER
A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.
Twardowski P, Kanaya N, Frankel P, Synold T, Ruel C, Pal SK, Junqueira M, Prajapati M, Moore T, Tryon P, Chen S. Cancer, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.